TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment
Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis
An examination of 10 CEFs with the highest duration risk.
We take a look at 2012's municipal CEF performance, distribution cuts, mergers, and more.
FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers